Market Place
Sourcing Support
All News #Library
Biotech
Transcenta Reveals Strong Anti-Tumor Activity Of ADC TST013
23 Apr 2026 //
GLOBENEWSWIRE
Transcenta Therapeutics To Present At Oppenheimer Healthcare
24 Feb 2026 //
GLOBENEWSWIRE
Transcenta Unveils Transtar102 First-Line Data at ESMO Asia
04 Dec 2025 //
GLOBENEWSWIRE
Transcenta Highlights LIV-1 ADC Efficacy In TNBC Tumor At SABCS
12 Dec 2024 //
PR NEWSWIRE
Transcenta Shows Efficacy of Osemitamab in G/GEJ Cancer at ESMO 2024
18 Sep 2024 //
PR NEWSWIRE
Transcenta collaborates Agilent to develop Claudin18.2 to support Osemitamab
09 Apr 2024 //
PHARMABIZ
Transcenta Announces the Publication of Results of [177Lu]Lu-TST001 Radionuclide Antibody Conjugate
13 Dec 2023 //
PR NEWSWIRE
Transcenta Unveils Data from Osemitamab as First-Line Treatment for G/GEJ Cancer
23 Oct 2023 //
PR NEWSWIRE
FDA Grants Transcenta Clearance to Proceed with Phase III Trial of Osemitamab
03 Oct 2023 //
PR NEWSWIRE
Transcenta Anti-sclerostin Monoclonal Antibody TST002 Received Approval
31 Jul 2023 //
PR NEWSWIRE
TST002 Received Approval from China CDE to Initiate Phase II Clinical Trial
30 Jul 2023 //
PR NEWSWIRE
Transcenta Presented PFS Data by CLDN18.2 Level from PhI/II Study of Osemitamab
30 Jun 2023 //
PR NEWSWIRE
Transcenta Presents Updated Data of Osemitamab in Combination with CAPOX
05 Jun 2023 //
PR NEWSWIRE
Transcenta Announces Encouraging Ph I Clinical Data of TST002
16 May 2023 //
PR NEWSWIRE
Transcenta to Present Two Clinical Trial Progress at ASCO 2023
08 May 2023 //
PR NEWSWIRE
Completion of Enrollment in Cohorts C and G of China PhII Study of Osemitamab
02 May 2023 //
PR NEWSWIRE
Transcenta Announces First Patient Dosed in the U.S. Study of Antibody TST003
22 Mar 2023 //
PR NEWSWIRE
Transcenta to Present Two Preclinical Studies at AACR 2023
22 Mar 2023 //
PR NEWSWIRE
Transcenta to Present "Trial in Progress" at ASCO-GI for TST001 with Nivolumab
17 Jan 2023 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.